OrchidPharma
A Dhanuka Group Company

August 20, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(ii) SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sub: Investors Presentation- Quarter I of F.Y. 2026-27, ended on June 30, 2026 – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and in continuation to our earlier intimation, dated August 17, 2026, regarding the Analysts/Investors Earning Call scheduled to be held on August 21, 2026 at 03:00 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-I of Financial Year 2026-27, ended on June 30, 2026.

The Investor Presentation is also made available on the website of the Company at https://www.orchidpharma.com/investors

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

KAPIL DAYYA

Digitally signed by KAPIL DAYYA
Date: 2026.08.20 17:38:59 +05'30'

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. as above

OrchidPharma
A Dhanuka Group Company

FROM
Soil to Vial

Nature Inspired Origins

Fermentation & Biotransformation

KSMs & API Process Development

API Manufacturing

Formulations & Fill Finish

Finished Dosage For A Healthier World

2026

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Orchid Pharma Limited (**the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Orchid Pharma Limited

OrchidPharma
A Dhanuka Group Company

One of the most **integrated** anti-infective platform globally

- Built on **30 years of cephalosporin expertise.**
- Proven by **EXBLIFEP - India's only novel antibiotic.**
- Anchored by **India's only USFDA sterile cephalosporin approval.**
- Extending into **AMR and regulated markets.**



An Integrated Cephalosporin Platform

Orchid is at an inflection point

The merger is complete and the platform is coming together as one

The core API business is ready to create long-term value

Multiple growth engines are moving from concept to execution across KSM, FDF, and Innovative drug products

STRATEGIC AMALGAMATION

Two entities. One Orchid.

Dhanuka Laboratories Ltd. amalgamated into
Orchid Pharma Ltd. under the NCLT-sanctioned Scheme.



APPOINTED DATE
1 April 2024

EFFECTIVE DATE
10 July 2026

Bringing two entities together

Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. ·

Dhanuka Laboratories Ltd.

THE ENTITY BEING INTEGRATED

- Pharma business established in 1998
- Leader in cephalosporin antibiotics across emerging markets
- Two API facilities – Cephalosporin & NPNC
- NPNC API facility –started in 2018
- NPNC Formulations facility started in 2019

+

Orchid Pharma Ltd.

- India's USFDA-approved sterile cephalosporin leader
- DLL's pharmaceutical capabilities absorbed under the sanctioned Scheme
- FY25 & FY26 results revised from the Appointed Date

OUTCOME **One integrated Orchid platform**

* FY26 results were initially approved on 25 May 2026, before the Scheme became effective, and were then revised to reflect the amalgamation from the Appointed Date.

Financial Performance

Q1 FY27

Q1 FY27 Financial Performance: **Standalone**

(Rs Cr)

(Amt. in Cr.)	Q1-27	Q1-26	% Change	FY 26	FY 25	% Change
Revenue from Operations	**304**	**263**	**+16%**	**1233**	**1397**	**-11%**
Other Income	10	16	-38%	56	36	+56%
COGS	204	184		844	893	
Employee Exp	27	28		114	109	
Other Exp	58	58		236	244	
EBITDA	**25**	**9**	**+178%**	**95**	**187**	**-49%**
% to Sales	8%	3%		8%	13%	
Interest	2	2		9	13	-13%
Depreciation	11	11		43	42	
Exceptional Items	1	0		(7)	0	
PAT	**12**	**-3**		**35**	**132**	

FY26 Financial Performance: **Standalone (Revised)**

OrchidPharma
A Dhanuka Group Company

(Rs Cr)

Total Revenue



EBITDA



PAT



Gross Margin



EBITDA Margin



Q1 FY27 Financial Performance : **Standalone**

OrchidPharma
A Dhanuka Group Company

(Rs Cr)

Total Revenue



EBITDA



PAT



Gross Margin



EBITDA Margin



Profit & Loss Statement (Standalone)

(Rs Cr)

Particulars	Q1 FY27 Jun 2026	Q1 FY26 Jun 2025	FY26 Year ended
Income			
Revenue from Operations	304.17	263.19	1,232.78
Other Income	10.05	16.05	56.49
Total Income	**314.22**	**279.24**	**1,289.27**
Expenses			
Cost of Materials Consumed	206.42	203.70	771.39
Changes in Inventories	(2.72)	(21.09)	71.38
Purchases of Stock-in-Trade	0.61	0.79	1.69
Employee Benefits Expense	26.76	27.70	114.32
Finance Costs	2.21	2.28	8.96
Depreciation & Amortisation	10.90	10.53	43.36
Other Expenses	58.11	57.74	236.21
Total Expenses	**302.28**	**281.64**	**1,247.31**
Profit/(Loss) Before Exceptional Items & Tax	**11.94**	**(2.41)**	**41.95**
Exceptional Items	–	–	(7.33)
Profit/(Loss) Before Tax	**11.94**	**(2.41)**	**34.62**
Tax Expense	–	–	–
Share of Profit/(Loss) of Associates & JV	–	–	–
Profit/(Loss) for the Period	**11.94**	**(2.41)**	**34.62**
Other Comprehensive Income (net of tax)	0.01	(0.15)	1.32
Total Comprehensive Income	**11.94**	**(2.56)**	**35.94**
EPS – Basic & Diluted (₹)	**1.99**	**(0.40)**	**5.78**

Profit & Loss Statement (Consolidated)

(Rs Cr)

Particulars	Q1 FY27 Jun 2026	Q1 FY26 Jun 2025	FY26 Year ended
Income			
Revenue from Operations	304.17	263.19	1,232.78
Other Income	1.83	11.57	36.42
Total Income	**306.00**	**274.76**	**1,269.20**
Expenses			
Cost of Materials Consumed	206.42	203.70	771.39
Changes in Inventories	(2.72)	(21.09)	71.38
Purchases of Stock-in-Trade	0.61	0.79	1.69
Employee Benefits Expense	28.04	27.70	117.65
Finance Costs	2.23	2.28	8.98
Depreciation & Amortisation	10.95	10.53	43.25
Other Expenses	57.83	57.74	237.09
Total Expenses	**303.35**	**281.65**	**1,251.43**
Profit/(Loss) Before Exceptional Items & Tax	**2.65**	**(6.89)**	**17.76**
Exceptional Items	–	–	(7.33)
Profit/(Loss) Before Tax	**2.65**	**(6.89)**	**10.43**
Tax Expense	0.07	–	(0.19)
Share of Profit/(Loss) of Associates & JV	0.65	1.20	(0.66)
Profit/(Loss) for the Period	**3.22**	**(5.69)**	**9.96**
Other Comprehensive Income (net of tax)	0.01	(0.15)	1.32
Total Comprehensive Income	**3.23**	**(5.85)**	**11.28**
EPS – Basic & Diluted (₹)	**0.54**	**(0.95)**	**1.66**

OrchidPharma™

A **Dhanuka** Group Company